The 2021 in-person Summit meeting is currently canceled in response to COVID-19 recommendations. In its place, in a manner similar to 2020, the Summit will be sponsoring a series of virtual meetings on topics of interest related to adult and influenza immunizations, and of course, the COVID-19 immunization programs.
Select a meeting title listed below to view a recording of each 2021 virtual event or to access individual presentations shared during the meeting. (Similar information is available for Summit meetings held during 2020.)
Be sure to check back on this page for announcements about upcoming webinars.
Developing COVID-19 Vaccines in Record Time, Part 4: Update on Vaccines
November 8, 2021, from 2:00–4:00 p.m. (ET)
COVID-19 Vaccine Update Part 4 – Updates from vaccine developers regarding COVID-19 vaccines for children and adults.
This webinar, supported by the National Adult and Influenza Immunization Summit (NAIIS), will feature updates from COVID-19 vaccine developers regarding COVID-19 vaccines for adults and children. This is the 4th in a series of webinars featuring vaccine manufacturers presenting their latest updates on COVID-19 vaccine research for specific populations, development, and roll out. We will feature presentations from companies with currently available COVID-19 vaccines, and/or vaccine candidates in later clinical trial phases (Phase 2/3) as well vaccines in earlier phases of clinical development. We are asking all companies to present updates on either: (1) published or other data plus timing of next phase of trials; (2) published Phase 2 data as well as a description and updates on the progress of Phase 3 trials; or (3) current vaccines and their roll out; availability of doses over the next few months; and/or other developments with regard to dosing or formulation that would be of interest to NAIIS partners.
After the presentations, there will be a moderated discussion of scientific and implementation topics: understanding of the variants/mutations of SARS-CoV2 and the vaccines; thoughts about duration of immunity, impact of vaccination on transmission, and industry thoughts on potential changes in formulations as the SARS-CoV-2 viruses continue to evolve. Questions for the attendees will also be taken.
This meeting will be moderated by Phyllis Arthur, Vice President, Infectious Diseases & Emerging Science Policy, at BIO. We at the Summit are delighted and grateful for this opportunity to collaborate with BIO on this important discussion.
This informative event mirrors the typical final day of the in-person Summit, which is currently cancelled for 2021 due to the ongoing COVID-19 pandemic. The agenda for this 2 and a half hour virtual meeting includes discussion on influenza communications plans (with an update from the CDC) for the upcoming flu season, improving coverage rates in high-risk patients, as well as updates from the influenza vaccine manufacturers.
At this follow-up to two virtual meetings on COVID-19 vaccines conducted by the National Adult and Influenza Immunization Summit (NAIIS) in 2020, 8 vaccine manufacturers presented information on their COVID-19 vaccines and/or vaccine candidates in later clinical trial phases (Phase 2/3), as well as vaccines in earlier phases of clinical development. Information presented included (1) published or other data plus timing of next trial phases; (2) published Phase 2 data as well as a description and update on progress of Phase 3 trials; or (3) current vaccines and their roll out. Presenters also discussed the availability of doses over the next few months and provided an update on any other studies underway or planned. After the presentations, a moderated discussion was held including topics such as understanding SARS-CoV2 variants/mutations and their impact on vaccines, manufacturer thoughts about the duration of immunity and interruption of transmission, and answers to questions from attendees.
The meeting was moderated by Phyllis Arthur, Vice President, Infectious Diseases & Diagnostics Policy, at BIO. The Summit was delighted and grateful for the opportunity to collaborate with BIO on this important virtual meeting.